60 Degrees Pharmaceuticals Announces Private Placement Funding
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a committed player in the pharmaceutical sector that specializes in innovative treatments for infectious diseases, has announced plans for a $4 million private placement. This funding will support their ongoing initiatives and strengthen their capacity to develop new medications. The announcement highlights the company's dedication to tackling major health challenges faced around the world.
Details of the Private Placement
The private placement will involve issuing approximately 2,898,551 shares of common stock along with accompanying warrants. Each share is priced at $1.38, and the deal also includes series A and short-term series B warrants, which allow the holder to purchase additional shares at the same price. The series A warrants will be valid for five years, while the series B warrants will be effective for 18 months following stockholder approval. The transaction is expected to close soon, pending standard closing conditions.
Role of H.C. Wainwright & Co.
H.C. Wainwright & Co. has been selected as the exclusive placement agent for this private funding initiative. Their expertise in capital markets is anticipated to ensure the smooth execution of this investment opportunity.
Projected Use of Funds
The funds raised from this private placement will primarily be allocated for working capital and to strengthen key areas such as general operations and the commercialization of Arakoda, their leading product aimed at malaria prevention. Additionally, it will support ongoing research and development efforts to expand their range of treatments for infectious diseases.
Company Overview
Founded in 2010, 60 Degrees Pharmaceuticals has established itself in the development and marketing of medicines for infectious diseases that affect millions globally. The company notably received FDA approval for ARAKODA® (tafenoquine), which plays a crucial role in malaria prevention. By collaborating with respected research organizations across various countries, 60 Degrees Pharmaceuticals aims to harness their expertise and resources for the best possible outcomes. With backing from both the U.S. Department of Defense and private investors like Knight Therapeutics Inc., the company is well-positioned for growth and further innovation.
Headquarters and Operations
Headquartered in Washington D.C., 60 Degrees Pharmaceuticals also has a significant operational presence through its majority-owned subsidiary in Australia. This geographical diversity enhances its research capabilities and connects it with international markets.
Frequently Asked Questions
What is the significance of the private placement?
This private placement provides 60 Degrees Pharmaceuticals with essential funding to further their drug development and operational strategies, particularly for their malaria prevention product and ongoing research and development efforts.
Who is the placement agent for this transaction?
H.C. Wainwright & Co. has been appointed as the exclusive placement agent, leveraging their extensive expertise to ensure a successful placement.
How will the funds be utilized?
The funds raised will be used for working capital, general operations, and the commercialization of Arakoda, in addition to supporting the company’s research and development initiatives.
When is the expected closing date for the funding?
The closing of the placement is expected to take place shortly, subject to the fulfillment of customary closing conditions.
What is the history of 60 Degrees Pharmaceuticals?
Established in 2010, 60 Degrees Pharmaceuticals focuses on innovative therapies for infectious diseases and received FDA approval for ARAKODA in 2018, marking a significant milestone in its development journey.
